These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31854307)

  • 41. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications.
    Relja B; Lustenberger T; Puttkammer B; Jakob H; Morser J; Gabazza EC; Takei Y; Marzi I
    Immunobiology; 2013 Apr; 218(4):470-6. PubMed ID: 22749979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
    Tobu M; Iqbal O; Fareed D; Chatha M; Hoppensteadt D; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):225-32. PubMed ID: 15247979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
    Verdú J; Marco P; Benlloch S; Sanchez J; Lucas J
    Thromb Haemost; 2006 Mar; 95(3):585-6. PubMed ID: 16525595
    [No Abstract]   [Full Text] [Related]  

  • 45. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study.
    Monasterio J; Bermúdez P; Quiroga D; Francisco E; Meneses B; Montaner J
    Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):382-6. PubMed ID: 15692248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
    Chhikara A; Sharma S; Chandra J; Nangia A
    Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy.
    Mousa HA; Downey C; Alfirevic Z; Toh CH
    Thromb Haemost; 2004 Nov; 92(5):1025-31. PubMed ID: 15543330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH; van Tilburg NH; Vos HL; Bertina RM; Rijken DC
    Br J Haematol; 2004 Mar; 124(5):659-65. PubMed ID: 14871254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
    Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
    Erem C; Kocak M; Nuhoglu I; Yılmaz M; Ucuncu O
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
    Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
    Schroeder V; Chatterjee T; Mehta H; Windecker S; Pham T; Devantay N; Meier B; Kohler HP
    Thromb Haemost; 2002 Dec; 88(6):1020-5. PubMed ID: 12529754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J; Tymcio J
    Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombin activatable fibrinolysis inhibitor as an indicator of the severity of acute pancreatitis.
    Radovanović-Dinić B; Tešić-Rajković S; Ignjatovic A; Grgov S
    Turk J Gastroenterol; 2018 Jul; 29(4):488-493. PubMed ID: 30249565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs.
    Jessen LR; Wiinberg B; Kjelgaard-Hansen M; Jensen AL; Rozanski E; Kristensen AT
    Vet Clin Pathol; 2010 Sep; 39(3):296-301. PubMed ID: 20487433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
    Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I; Morange PE; Aubert H; Henry M; Aillaud MF; Alessi MC; Samnegård A; Hawe E; Yudkin J; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):867-73. PubMed ID: 12006404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
    Bajzar L; Jain N; Wang P; Walker JB
    Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
    Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.